These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 37427115)

  • 1. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.
    Czajka-Francuz P; Prendes MJ; Mankan A; Quintana Á; Pabla S; Ramkissoon S; Jensen TJ; Peiró S; Severson EA; Achyut BR; Vidal L; Poelman M; Saini KS
    Front Oncol; 2023; 13():1200646. PubMed ID: 37427115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
    Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
    Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.
    Xu Y; Xiong J; Sun X; Gao H
    Acta Pharm Sin B; 2022 Dec; 12(12):4327-4347. PubMed ID: 36561994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.
    Pan X; Zheng L
    Cell Mol Immunol; 2020 Sep; 17(9):940-953. PubMed ID: 32699350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
    Salemme V; Centonze G; Cavallo F; Defilippi P; Conti L
    Front Oncol; 2021; 11():610303. PubMed ID: 33777750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
    Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
    Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
    Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
    Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
    Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
    Peters S; Paz-Ares L; Herbst RS; Reck M
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
    O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
    Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
    Chyuan IT; Chu CL; Hsu PN
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
    Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic inflammation, cancer development and immunotherapy.
    Wen Y; Zhu Y; Zhang C; Yang X; Gao Y; Li M; Yang H; Liu T; Tang H
    Front Pharmacol; 2022; 13():1040163. PubMed ID: 36313280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance.
    Jiang T; Chen X; Ren X; Yang JM; Cheng Y
    Drug Resist Updat; 2021 May; 56():100752. PubMed ID: 33765484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.